Literature DB >> 7178821

Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones.

O Leiss, K von Bergmann.   

Abstract

The effect on serum lipoprotein concentrations of chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) was examined in eight normolipemic patients with radiolucent gallstones during constant liquid formula infusion into the duodenum. Every patient received each bile acid (1000 mg/day) during two consecutive randomized 4-week periods. During treatment with CDCA but not UDCA, the serum triglycerides decreased by an average of 26%. Mean HDL cholesterol decreased by 46% during CDCA therapy and remained unchanged during UDCA administration. Simultaneous measurements of biliary lipid secretion showed a significant negative correlation between HDL cholesterol concentration and hepatic secretion of CDCA (r = -0.652) and a positive correlation between the LDL cholesterol/HDL cholesterol ratio and hepatic secretion of CDCA (r = 0.840). Despite their close chemical relationships and similar effects on biliary lipids, CDCA and UDCA differ markedly in their effects on serum lipoproteins. Because of this and minor side effects, UDCA seems to be a safer agent than CDCA for cholesterol gallstone dissolution.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7178821     DOI: 10.3109/00365528209181063

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  11 in total

1.  Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice.

Authors:  Thomas Gautier; Willeke de Haan; Jacques Grober; Dan Ye; Matthias J Bahr; Thierry Claudel; Niels Nijstad; Theo J C Van Berkel; Louis M Havekes; Michael P Manns; Stefan M Willems; Pancras C W Hogendoorn; Laurent Lagrost; Folkert Kuipers; Miranda Van Eck; Patrick C N Rensen; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2013-04-25       Impact factor: 5.922

2.  Cholesterol absorption and sterol balance in normal subjects receiving dietary fiber or ursodeoxycholic acid.

Authors:  G Salvioli; R Lugli; J M Pradelli
Journal:  Dig Dis Sci       Date:  1985-04       Impact factor: 3.199

Review 3.  Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.

Authors:  Geoffrey Porez; Janne Prawitt; Barbara Gross; Bart Staels
Journal:  J Lipid Res       Date:  2012-05-01       Impact factor: 5.922

4.  Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor.

Authors:  Christophe Gardès; Denise Blum; Konrad Bleicher; Evelyne Chaput; Martin Ebeling; Peter Hartman; Corinne Handschin; Hans Richter; G Martin Benson
Journal:  J Lipid Res       Date:  2011-04-04       Impact factor: 5.922

5.  Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element.

Authors:  Thierry Claudel; Ekkehard Sturm; Hélène Duez; Inés Pineda Torra; Audrey Sirvent; Vladimir Kosykh; Jean-Charles Fruchart; Jean Dallongeville; Dean W Hum; Folkert Kuipers; Bart Staels
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

6.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

Authors:  Changtao Jiang; Cen Xie; Fei Li; Limin Zhang; Robert G Nichols; Kristopher W Krausz; Jingwei Cai; Yunpeng Qi; Zhong-Ze Fang; Shogo Takahashi; Naoki Tanaka; Dhimant Desai; Shantu G Amin; Istvan Albert; Andrew D Patterson; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

Review 7.  Nuclear bile acid signaling through the farnesoid X receptor.

Authors:  Claire Mazuy; Audrey Helleboid; Bart Staels; Philippe Lefebvre
Journal:  Cell Mol Life Sci       Date:  2014-12-16       Impact factor: 9.261

8.  [Relation between serum lipoprotein metabolism and biliary lipid metabolism].

Authors:  O Leiss; K von Bergmann
Journal:  Klin Wochenschr       Date:  1983-06-15

Review 9.  Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

Review 10.  Endocrine functions of bile acids.

Authors:  Sander M Houten; Mitsuhiro Watanabe; Johan Auwerx
Journal:  EMBO J       Date:  2006-03-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.